Dyne Therapeutics (NASDAQ: DYN) director Barry Greene files initial Form 3
Rhea-AI Filing Summary
Dyne Therapeutics, Inc. director Barry E. Greene filed an initial Form 3 ownership report. This filing identifies him as a director of the company and, in the data provided, shows no reported transactions or derivative positions, with all buy, sell, and exercise counts at zero.
Positive
- None.
Negative
- None.
Key Figures
Buy transactions: 0
Sell transactions: 0
Net buy/sell shares: 0
+2 more
5 metrics
Buy transactions
0
BuyCount in Form 3 data
Sell transactions
0
SellCount in Form 3 data
Net buy/sell shares
0
netBuySellShares in Form 3
Derivative transactions
0
derivativeTransactionCount in Form 3
Holding entries
0
holdingEntries in Form 3 data
Key Terms
Form 3, reporting person, derivative securities
3 terms
Form 3 regulatory
"Initial statement of beneficial ownership on Form 3 for a director."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
reporting person regulatory
"Barry E. Greene is identified as a reporting person and director."
derivative securities financial
"The derivativeSummary section shows no derivative securities reported."
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Dyne Therapeutics (DYN) Form 3 for Barry E. Greene show?
The Form 3 for Dyne Therapeutics director Barry E. Greene records his status as a reporting person. The provided data show zero transactions, zero derivative positions, and a neutral net share change, serving as an initial ownership disclosure.
Are there any derivative securities disclosed for Barry E. Greene in Dyne Therapeutics’ Form 3?
No derivative securities are listed in the provided data. The derivativeSummary is empty and derivativeTransactionCount is zero, indicating no options, warrants, or similar instruments are reported in this Form 3 excerpt.
What is the net buy/sell direction in the Dyne Therapeutics (DYN) Form 3 data?
The net buy/sell direction is labeled neutral with netBuySellShares at zero. This means the provided Form 3 data show no net increase or decrease in reported share ownership from transactions.
What role does Barry E. Greene hold at Dyne Therapeutics according to the Form 3?
Barry E. Greene is identified as a director of Dyne Therapeutics. The Form 3 flags him as a director-level reporting person, triggering ongoing ownership and transaction reporting obligations under SEC rules.